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Abstract
Osteoporotic fracture is a major cause of morbidity and mortality worldwide. Low bone mineral density (BMD) is a major
predisposing factor to fracture and is known to be highly heritable. Site-, gender-, and age-specific genetic effects on BMD
are thought to be significant, but have largely not been considered in the design of genome-wide association studies
(GWAS) of BMD to date. We report here a GWAS using a novel study design focusing on women of a specific age
(postmenopausal women, age 55–85 years), with either extreme high or low hip BMD (age- and gender-adjusted BMD z-
scores of +1.5 to +4.0, n = 1055, or 24.0 to 21.5, n = 900), with replication in cohorts of women drawn from the general
population (n = 20,898). The study replicates 21 of 26 known BMD–associated genes. Additionally, we report suggestive
association of a further six new genetic associations in or around the genes CLCN7, GALNT3, IBSP, LTBP3, RSPO3, and SOX4,
with replication in two independent datasets. A novel mouse model with a loss-of-function mutation in GALNT3 is also
reported, which has high bone mass, supporting the involvement of this gene in BMD determination. In addition to
identifying further genes associated with BMD, this study confirms the efficiency of extreme-truncate selection designs for
quantitative trait association studies.
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Introduction
Osteoporotic fracture is a leading cause of morbidity and
mortality in the community, particularly amongst the elderly. In
2004 ten million Americans were estimated to have osteoporosis,
resulting in 1.5 million fractures per annum [1]. Hip fracture is
associated with a one year mortality rate of 36% in men and 21%
in women [2]; and the burden of disease of osteoporotic fractures
overall is similar to that of colorectal cancer and greater than that
of hypertension and breast cancer [3]. Bone mineral density
(BMD) is strongly correlated with bone strength and fracture risk,
and its measurement is widely used as a diagnostic tool in the
assessment of fracture risk [4–6]. BMD is known to be highly
heritable, with heritability assessed in both young and elderly
twins, and in families, to be 60–90% [7–14]. Although the extent
of covariance between BMD and fracture risk is uncertain, of the
26 genes associated with BMD at genome-wide significant levels to
date, nine have been associated with fracture risk (reviewed in
[15]), supporting the use of BMD as an intermediate phenotype in
the search for genes associated with fracture risk.
There is considerable evidence from genetic studies in humans
[12,16,17], and in mice [18], indicating that the genes that
influence BMD at different sites, and in the different genders,
overlap but are not identical. Thus far all genome-wide association
studies (GWAS) of BMD have studied cohorts of a wide age range,
and with one exception have included both men and women;
when only women have been studied, both pre- and postmeno-
pausal women have been included. Therefore, to identify genes
involved in osteoporosis in the demographic at highest risk of
osteoporotic fracture we have performed a GWAS in postmen-
opausal women selected on the basis of their hip BMD, and
replicated the GWAS findings in a large cohort of adult women
drawn from the general population.
Results
Considering markers previously reported as associated with
BMD, our discovery dataset replicates previously associated SNPs
in 21 of the 26 genes reported to date to have genome-wide
significant associations (Table S6) (P,0.05, association in the same
direction as initially reported, or, in the case of LRP5 and GPR177,
with the next flanking SNP genotyped) [17,21,22,23,28,32,33,34].
Replicated genes include ARHGAP1, CTNNB1, ESR1, FAM3C,
FLJ42280, FOXL1, GPR177, HDAC5, JAG1, LRP5, MARK3,
MEF2C, MEPE, OPG, RANK, RANKL, SOST, SOX6, SP7 (Osterix),
STARD3NL and ZBTB40. Considering the combined Anglo-
Australasian Osteoporosis Genetics Consortium (AOGC) and
deCODE/TwinsUK/Rotterdam cohorts, 97 SNPs from six loci
achieved P,561028 at the femoral neck (FN), of which four had
previously been reported (FLJ42280, MEF2C, SOX6, ZBTB40). At
the lumbar spine (LS), six SNPs from two known loci (RANKL,
OPG) achieved P,561028. No support was seen for previously
reported associations involving SNPs in ADAMTS18, CRHR1,
DCDC5, MHC, or SBTBN1 (P.0.05).
This study also identifies and replicates two novel loci with
confirmed association with BMD in GALNT3 (MIM: 601756) and
at chromosome 6q22 near RSPO3 (MIM: 610574), and provides
strong evidence of a further four BMD-associated loci (CLCN7
(MIM: 602727), IBSP (MIM: 147563), LTBP3 (MIM: 602090),
SOX4 (MIM: 184430)) (Table 1). Although these did not achieve
‘genome-wide significance’ in the discovery set alone, they
achieved P-values in the AOGC-discovery cohort of P,1024,
and support in the AOGC-replication cohort, TwinsUK,
Rotterdam and deCODE cohorts; and all have additional
evidence supporting their role in bone. Support was also seen
for TGFBR3 (MIM: 600742), a gene previously reported to have
suggestive association with BMD [33].
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GALNT3
SNPs at chromosome 2q24, in and around GALNT3, achieved
near genome-wide significance in our discovery cohort (peak P-
value rs1863196, total hip (TH) P= 2.361025; LS P= 0.037)
(Figure 1A). This SNP was not typed or imputed by either the
Rotterdam or the TwinsUK cohorts, but a nearby SNP showed
strong association in both AOGC and the combined replication
cohorts (rs6710518; AOGC discovery, TH P=6.961025; com-
bined replication sets, FN P= 2.761027). In the combined
datasets the finding achieved genome-wide significance at the
FN (P= 1.7610210). Strong association was also seen with this
SNP at LS (P= 7.561025). Another marker within GALNT3,
rs4667492, was also associated with fracture risk, including
vertebral fractures (OR=0.89; 95%CI= 0.80–0.99; P= 0.032)
and overall low trauma fractures (OR=0.92; 95%CI= 0.85–0.99;
P = 0.024).
We have recently identified a mouse with an N-ethyl-N-
nitrosourea induced loss-of-function GALNT3 mutation
(Trp589Arg), that develops hyperphosphataemia with extraskeletal
calcium deposition, and hence represents a model for FTC [35].
To establish further the association of GALNT3 and BMD, we
determined BMD in these GALNT3 mutant mice. This revealed
that homozygous (2/2) GALNT3 mutant male and female adult
mice had a higher areal BMD than their wild-type (+/+) litter
mates, with heterozygous (+/2) mice having intermediate BMD
(Figure 2). This loss-of-function GALNT3 mutation is predicted to
lead to a reduced glycosylation of FGF23, which increases its
breakdown and leads to reduced serum FGF23 concentrations
[35].
RSPO3
A novel genome-wide significant association was also seen at
markers on chromosome 6q22-23 (Figure 1B). In the combined
dataset, marker rs13204965 achieved genome-wide significance at
this locus at the FN (P= 2.261029), with strong support in both the
AOGC discovery set, and the combined replication sets (AOGC-
discovery, TH P=2.161024; combined replication P=3.561025).
Strong association was also seen with LS BMD (rs13204965
P=0.00067). The peak of association at this locus lies within a
cDNA fragment, AK127472. The nearest gene, RSPO3 (R-spondin-
3), is 275 kb telomeric of the strongest associated SNP, but is within
the associated linkage disequilibrium region (Figure 1B).
CLCN7
Association was observed at chromosome 16p13 with SNPs
in and around CLCN7, which encodes a Cl2/H+ antiporter
expressed primarily in osteoclasts, and critical to lysosomal
acidification, an essential process in bone resorption. Peak
association at this locus was seen with SNP rs13336428 in the
discovery set (TH P=7.061024; LS P= 0.028) (Figure S3A),
which was confirmed in the replication set (FN P= 3.661025; LS
P= 0.00012), achieving P= 1.761026 at the FN and 1.261025 at
LS in the overall cohort. Association has previously been reported
between two SNPs in exon 15 of CLCN7 (rs12926089, rs12926669)
and FN BMD (P= 0.001–0.003) [36]; no association was seen with
either of those SNPs in the current study (P.0.4 at FN and LS).
IBSP
Association was observed with SNPs in IBSP (integrin-binding
bone sialoprotein) (Figure S3B), encoded at chromosome 4q22, a
gene which has previously had suggestive association reported with
BMD in two studies (rs1054627, Styrkarrsdottir et al P= 4.661025
[22]; Koller et al P= 1.561024 [37]). In the current study,
moderate association was observed in the discovery set with the
same SNP as previously reported (rs1054627, AOGC discovery
TH, P= 6.661025), with support in the replication set and strong
association overall (FN combined replication P= 9.261025; FN
overall association P=7.661027). Nominal association was
observed at LS (rs1054627, P= 0.019).
LTBP3
Association with BMD was also seen at chromosome 11p13,
with SNP rs1152620 achieving P= 4.461025 (TH) in the
discovery set, P = 0.0051 (FN) in the replication set, and
P= 3.661024 overall (Figure S3C). This SNP was also nominally
associated with LS BMD in the discovery set (P = 0.041). The
nearest gene to this locus is LTBP3 (latent transforming growth
factor beta binding protein 3), which is located 292 kb q-telomeric
of rs1152620.
SOX4
At chromosome 6p22, SNPs in and around SOX4 (Sex
determining region Y box 4) were moderately associated with
BMD in our discovery set (most significant association rs9466056,
TH P=5.361024; LS P= 0.0036) (Figure S3D), with support at
the hip and LS in the replication set (FN P= 0.00013, LS
P= 0.013), achieving association overall with P= 2.661027 (FN)
and P=0.00081 (LS).
Discussion
This study demonstrates convincing evidence of association with
six genes with BMD variation, GALNT3, RSPO3, CLCN7, IBSP,
LTBP3 and SOX4. Using a moderate sample size, the use of a
novel study design also led to the confirmation of 21 of 26 known
BMD-associations. This study thus demonstrates the power of
extreme-truncate selection designs for association studies of
quantitative traits.
GALNT3 encodes N-acetylgalactosaminyltransferase 3, an
enzyme involved in 0-glycosylation of serine and threonine
residues. Mutations of GALNT3 are known to cause familial
tumoral calcinosis (FTC, OMIM 2111900) [38] and hyperostosis-
hyperphosphataemia syndrome (HOHP, OMIM 610233) [39].
FTC is characterised by hyperphosphataemia in association with
the deposition of calcium phosphate crystals in extraskeletal
tissues; whereas in HOHP, hyperphosphataemia is associated with
recurrent painful long bone swelling and radiographic evidence of
Author Summary
Osteoporotic fracture is a major cause of early mortality
and morbidity in the community. To identify genes
associated with osteoporosis, we have performed a
genome-wide association study. In order to improve study
power and to address the demographic group of highest
risk from osteoporotic fracture, we have used a unique
study design, studying 1,955 postmenopausal women with
either extreme high or low hip bone mineral density. We
then confirmed our findings in 20,898 women from the
general population. Our study replicated 21 of 26 known
osteoporosis genes, and it identified a further six novel loci
(in or nearby CLCN7, GALNT3, IBSP, LTBP3, RSPO3, and
SOX4). For one of these loci, GALTN3, we demonstrate in a
mouse model that a loss-of-function genetic mutation in
GALNT3 causes high bone mass. These findings report
novel mechanisms by which osteoporosis can arise, and
they significantly add to our understanding of the
aetiology of the disease.
Genetics of Osteoporosis
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periosteal reaction and cortical hyperostosis. FGF23 mutations
associated with FTC cause hyperphosphataemia through effects
on expression of the sodium-phosphate co-transporter in the
kidney and small intestine, and through increased activation of
vitamin D due to increased renal expression of CYP27B1 (25-
hydroxyvitamin-D 1 alpha hydroxylase) [40]. It is unclear whether
FGF23 has direct effects on the skeleton or if its effects are
mediated through its effects on serum phosphate and vitamin D
levels. FGF23 signals via a complex of an FGF receptor
(FGFR1(IIIc)) and Klotho [41]; mice with a loss-of-function
mutation in Klotho develop osteoporosis amongst other abnormal-
ities, and modest evidence of association of Klotho with BMD has
been reported in several studies [42,43,44,45]. We saw no
association with polymorphisms in Klotho and BMD in the current
study (P.0.05 for all SNPs in and surrounding Klotho). To our
knowledge, this finding is the first demonstration in humans that
genetic variants in the FGF23 pathway are associated with any
common human disease.
RSPO3 is one of four members of the R-spondin family (R-
spondin-1 to 24), which are known to activate the Wnt pathway,
particularly through effects on LRP6, itself previously reported to
be BMD-associated [46,47]. LRP6 is inhibited by the proteins
Kremen and DKK1, which combine to induce endocytosis of
LRP6, reducing its cell surface levels. R-spondin family members
have been shown to disrupt DKK1-dependent association of
LRP6 and Kremen, thereby releasing LRP6 from this inhibitory
pathway [48]. R-spondin-4 mutations cause anonychia (absence or
severe hypoplasia of all fingernails and toenails, OMIM 206800)
[49]. No human disease has been associated with R-spondin-3,
and knockout of R-spondin-3 in mice is embryonically lethal due
to defective placental development [50].
Mutations of CLCN7 cause a family of osteopetroses of differing
age of presentation and severity, including infantile malignant
CLCN7-related recessive osteopetrosis (ARO), intermediate auto-
somal osteopetrosis (IAO), and autosomal dominant osteopetrosis
type II (ADOII, Albers-Schoenberg disease). These conditions are
characterized by expanded, dense bones, with markedly reduced
bone resorption. Our data support associations of polymorphisms
at this locus with BMD variation in the population.
IBSP is a major non-collagenous bone matrix protein involved
in calcium and hydroxyapatite binding, and is thought to play a
role in cell-matrix interactions through RGD motifs in its amino
acid sequence. IBSP is expressed in all major bone cells including
osteoblasts, osteocytes and osteoclasts; and its expression is
upregulated in osteoporotic bone [51]. IBSP knockout mice have
low cortical but high trabecular bone volume, with impaired bone
formation, resorption, and mineralization [52]. IBSP lies within a
cluster of genes including DMP1, MEPE, and SPP1, all of which
have known roles in bone and are strong candidate genes for
association with BMD. MEPE has previously been associated with
BMD at genome-wide significance [17]. In the current study the
strongest association was seen with an SNP in IBSP, rs1054627, as
was the case with two previous studies [22,37]. Linkage
disequilibrium between this SNP, and the previously reported
BMD-associated SNP rs1471403 in MEPE, is modest (r2 = 0.16).
Whilst out study supports the association of common variants in
IBSP in particular with BMD, further studies will be required to
determine if more than one of these genes is BMD-associated.
Recessive mutations of LTBP3 have been identified as the cause
of dental agenesis in a consanguineous Pakistani family (OMIM
613097) [53]. Affected family members had base of skull
thickening, and elevated axial but not hip BMD. LTBP32/2
mice develop axial osteosclerosis with increased trabecular bone
thickness, as well as craniosynostosis [54]. LTBP3 is known to bind
T
a
b
le
1
.
Fi
n
d
in
g
s
fo
r
n
o
ve
l
re
p
lic
at
e
d
as
so
ci
at
io
n
s.
A
O
G
C
D
IS
C
O
V
E
R
Y
R
E
P
L
IC
A
T
IO
N
C
O
M
B
IN
E
D
D
IS
C
O
V
E
R
Y
/R
E
P
L
IC
A
T
IO
N
T
H
F
N
L
S
F
N
L
S
F
N
L
S
L
O
C
U
S
S
N
P
A
1
/A
2
G
E
N
E
B
E
T
A
P
-V
A
L
U
E
B
E
T
A
P
-V
A
L
U
E
B
E
T
A
P
-V
A
L
U
E
B
E
T
A
P
-V
A
L
U
E
B
E
T
A
P
-V
A
L
U
E
B
E
T
A
P
-V
A
L
U
E
B
E
T
A
P
-V
A
L
U
E
2
q
2
4
rs
1
8
6
3
1
9
6
A
/G
G
A
LN
T3
0
.2
8
4
2
.3
6
1
0
-5
2
0
.0
9
0
3
.7
6
1
0
2
5
2
0
.0
6
8
0
.0
3
7
2
0
.0
6
5
0
.0
0
1
1
2
0
.0
1
0
.7
2
2
0
.0
7
7
2
.0
6
1
0
2
7
2
0
.0
2
4
0
.1
6
2
q
2
4
rs
6
7
1
0
5
1
8
C
/T
G
A
LN
T3
0
.2
6
2
6
.9
6
1
0
2
5
2
0
.0
7
8
0
.0
0
1
5
2
0
.0
6
8
0
.0
3
9
2
0
.0
5
7
1
.2
6
1
0
2
6
2
0
.0
3
7
0
.0
1
2
0
.0
6
4
4
.8
6
1
0
2
1
0
2
0
.0
4
2
0
.0
0
1
7
4
q
2
2
rs
1
0
5
4
6
2
7
A
/G
IB
SP
0
.2
7
7
6
.6
6
1
0
2
5
2
0
.0
4
2
0
.0
0
0
2
4
2
0
.0
4
9
0
.1
8
2
0
.0
4
3
9
.2
6
1
0
2
5
2
0
.0
2
7
0
.0
4
6
2
0
.0
5
0
7
.6
6
1
0
2
7
2
0
.0
3
0
.0
1
9
6
p
2
2
rs
9
4
6
6
0
5
6
A
/G
SO
X
4
2
0
.2
3
7
5
.3
6
1
0
2
4
0
.0
9
0
6
.6
6
1
0
2
5
0
.1
0
0
.0
0
3
6
0
.0
3
3
0
.0
0
3
3
0
.0
2
1
0
.1
7
0
.0
4
9
4
.2
6
1
0
2
6
0
.0
3
5
0
.0
1
4
6
q
2
2
rs
1
7
5
6
3
6
0
5
T
/C
R
SP
O
3
0
.3
0
2
.1
6
1
0
2
4
2
0
.1
0
7
.4
6
1
0
2
5
2
0
.0
8
8
0
.0
2
0
2
0
.0
5
1
2
.1
6
1
0
2
4
2
0
.0
4
7
0
.0
0
9
7
2
0
.0
6
2
2
.5
6
1
0
2
7
2
0
.0
5
5
0
.0
0
0
8
2
6
q
2
2
rs
1
3
2
0
4
9
6
5
A
/C
R
SP
O
3
0
.3
0
2
.1
6
1
0
2
4
2
0
.1
0
7
.3
6
1
0
2
5
2
0
.0
8
9
0
.0
2
0
2
0
.0
5
7
3
.5
6
1
0
2
5
2
0
.0
4
9
0
.0
0
8
2
2
0
.0
6
7
3
.0
6
1
0
2
8
2
0
.0
5
6
0
.0
0
0
6
7
1
1
p
1
3
rs
1
1
5
2
6
2
0
A
/G
LT
B
P
3
2
0
.3
1
1
4
.4
6
1
0
2
5
0
.0
6
0
0
.0
2
0
0
.0
8
0
0
.0
4
1
0
.0
3
9
0
.0
0
5
1
0
.0
1
3
0
.4
8
0
.0
4
4
3
.6
6
1
0
2
4
0
.0
2
5
0
.1
3
1
6
p
1
3
rs
1
3
3
3
6
4
2
8
A
/G
C
LC
N
7
2
0
.2
2
1
7
.0
6
1
0
2
4
0
.0
5
7
0
.0
1
3
0
.0
7
6
0
.0
2
8
0
.0
4
0
0
.0
0
1
1
0
.0
4
5
0
.0
0
5
0
0
.0
4
4
5
.1
6
1
0
2
5
0
.0
5
1
5
.1
6
1
0
2
4
Fi
n
d
in
g
s
fo
r
n
o
ve
l
re
p
lic
at
e
d
as
so
ci
at
io
n
s
fo
r
th
e
A
O
G
C
d
is
co
ve
ry
an
d
re
p
lic
at
io
n
se
ts
,
co
m
b
in
e
d
re
p
lic
at
io
n
se
ts
(A
O
G
C
re
p
lic
at
io
n
/T
w
in
sU
K
/R
o
tt
e
rd
am
/d
e
C
O
D
E)
an
d
e
n
ti
re
d
at
as
e
t
(A
O
G
C
d
is
co
ve
ry
an
d
re
p
lic
at
io
n
/T
w
in
sU
K
/
R
o
tt
e
rd
am
/d
e
C
O
D
E)
.T
h
e
re
g
re
ss
io
n
co
e
ff
ic
ie
n
t
in
th
e
T
H
an
al
ys
is
sh
o
w
s
th
e
e
xp
e
ct
e
d
in
cr
e
as
e
in
th
e
lo
g
o
d
d
s
ra
ti
o
o
f
lo
w
B
M
D
p
e
r
ad
d
it
io
n
o
f
al
le
le
A
2
.T
h
e
re
g
re
ss
io
n
co
e
ff
ic
ie
n
ts
in
th
e
FN
an
d
LS
an
al
ys
e
s
re
fe
r
to
th
e
e
xp
e
ct
e
d
in
cr
e
as
e
in
st
an
d
ar
d
iz
e
d
B
M
D
p
e
r
ad
d
it
io
n
o
f
al
le
le
A
2
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
g
e
n
.1
0
0
1
3
7
2
.t
0
0
1
Genetics of Osteoporosis
PLoS Genetics | www.plosgenetics.org 4 April 2011 | Volume 7 | Issue 4 | e1001372
Figure 1. SNP association plots for BMD-associated regions. Discovery cohort association significance level is plotted against the left hand y-
axis as -log10(P-values). Genetic coordinates are as per NCBI build 36.1. Filled circles represent genotyped SNPs, and outlined diamonds represent
imputed SNPs. The recombination rate (cM/Mb as per HapMap data) is indicated by the purple dotted line and right hand y-axis. Genes and ESTs are
indicated with their approximate sizes and direction of translation. (A) Chromosome 2q24 - GALNT3 region. SNP association plot of findings from TH
case-control analysis of AOGC discovery set for a 500 kb region (166,100 kb to 166,600 kb) of chromosome 2. LD is indicated by colour scale in
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TGFb1, -b2 and -b3, and may influence chondrocyte maturation
and enchondral ossification by effects on their bioavailability [54].
Our study also confirms the previously reported association of
another TGF pathway gene, TGFBR3, encoded at chromosome
1p22, with BMD [33] (Figure S3E). In that study, association was
observed in four independent datasets, but overall the findings did
not achieve genome-wide significance at any individual SNP (most
significant SNP rs17131547, P = 1.561026). In our discovery set,
peak association was seen at this locus with SNP rs7550034 (TH
P=1.561024), which lies 154 kb q-telomeric of rs17131547, but
still within TGFBR3 (rs17131547 was not typed or imputed in our
dataset) (Figure S3E). This supports TGFBR3 as a true BMD-
associated gene.
This study also demonstrated that SOX4 polymorphisms are
associated with BMD variation. Both SOX4 and SOX6 are
cartilage-expressed transcription factors known to play essential
roles in chondrocyte differentiation and cartilage formation, and
hence endochondral bone formation. SOX6 has previously been
reported to be BMD-associated at genome-wide significant levels
[17]. Whilst SOX42/2 mice develop severe cardiac abnormalities
and are non-viable, SOX4+/2 mice have osteopaenia with
reduced bone formation but normal resorption rates, and
diminished cortical and trabecular bone volume [55]. Our data
suggest that SOX4 polymorphisms contribute to the variation in
BMD in humans.
This study has a unique design amongst GWAS of BMD
reported to date, using an extreme-truncate ascertainment
scheme, focusing on a specific skeletal site (TH), and with
recruitment of a narrow age- and gender-group (post-menopausal
women age 55–85 years). Our goal in employing this scheme was
relationship to marker rs1863196. (B) Chromosome 6q22 - RSPO3 region. SNP association plot of findings from TH case-control analysis of AOGC
discovery set for a 1,200 kb region (126,600 kb to 127,800 kb) of chromosome 6. LD is indicated by colour scale in relationship to marker rs13204965.
doi:10.1371/journal.pgen.1001372.g001
Figure 2. Areal BMD derived from DEXA analysis of 15- to 16-week-old GALNT3mutant and wild-type mice. P-values refer to Student t-
test for two-way ANOVA across the three genotypes.
doi:10.1371/journal.pgen.1001372.g002
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to increase the study power by reducing heterogeneity due to age-,
gender- and skeletal site-specific effects. Whilst osteoporotic
fracture can occur at a wide range of skeletal sites, hip fracture
in postmenopausal women is the major cause of morbidity and
mortality due to osteoporosis. To date, with only one exception, all
GWAS of BMD have studied cohorts unselected for BMD [28],
and no study has restricted its participants to postmenopausal
women ascertained purely on the basis of hip BMD. Assuming
marker-disease-associated allele linkage disequilibrium of r2 = 0.9,
for alpha= 561028 our study has 80% power to detect variants
contributing 0.3% of the additive genetic variance of BMD. An
equivalent-powered cohort study would require ,16,000 unse-
lected cases.
Considering the 26 known genes (or genomic areas) associated
with BMD, P-values less than,0.05 were seen in our discovery for
21 of the BMD-associated SNPs. Of the 26 known BMD genes, 16
would have been included in our replication study on the basis of
the strength of their BMD association in our discovery cohort, but
were not further genotyped as they were known already to be
BMD-associated. Had these 16 genes replicated, 22 genes would
have been identified in this single study, demonstrating the power
of the design of the current study.
A potential criticism of studies of highly selected cohorts, such as
the AOGC-discovery cohort, is that the associations identified may
not be relevant in the general population. However, the
confirmation of our findings in replication cohorts of women
unselected for BMD confirms that our findings are of broad
relevance.
In summary, our study design therefore represents a highly
efficient model for future studies of quantitative traits and is one of
the first reported studies using an extreme truncate design in any
disease. We have identified two new BMD loci at genome-wide
significance (GALNT3, RSPO3), with GALNT3 SNPs also associated
with fracture. Strong evidence was also demonstrated for four
novel loci (CLCN7, IBSP, LTBP3, SOX4). Further support was also
provided that TGFBR3 is a true BMD-associated locus. Our
discovery cohort replicated 21 of 26 previously identified BMD-
associated loci. Our novel findings further advance our under-
standing of the aetiopathogenesis of osteoporosis, and highlight
new genes and pathways not previously considered important in
BMD variation and fracture risk in the general population. Our
study also provides strong support that the use of extreme truncate
selection is an efficient and powerful approach for the study of
quantitative traits.
Materials and Methods
Ethics statement
All participants gave written, informed consent, and the study
was approved by the relevant research ethics authorities at each
participating centre.
Subjects and phenotypes
The discovery sample population included 1128 Australian, 74
New Zealand and 753 British women, between 55–85 years of age,
five or more years postmenopausal, with either high BMD (age-
and gender-adjusted BMD z-scores of +1.5 to +4.0, n= 1055) or
low BMD (age- and gender-adjusted BMD z-scores of 24.0 to
21.5, n = 900) (Tables S1 and S2). BMD z-scores were
determined according to the Geelong Osteoporosis Study
normative range [19]. Low BMD cases were excluded if they
had secondary causes of osteoporosis, including corticosteroid
usage at doses equivalent to prednisolone $7.5 mg/day for $6
months, past or current anticonvulsant usage, previous strontium
usage, premature menopause (,45 years), alcohol excess (.28
units/week), chronic renal or liver disease, Cushing’s syndrome,
hyperparathyroidism, thyrotoxicosis, anorexia nervosa, malab-
sorption, coeliac disease, rheumatoid arthritis, ankylosing spondy-
litis, inflammatory bowel disease, osteomalacia, and neoplasia
(cancer, other than skin cancer). Screening blood tests (including
creatinine (adjusted for weight), alkaline phosphatase, gamma-
glutamyl transferase, 25-hydroxyvitamin D and PTH) were
checked in 776 cases, and no differences were found between
the high and low BMD groups. Therefore no further screening
tests were done of the remaining cases.
Fracture data were analysed comparing individuals who had
never reported a fracture after the age of 50 years, with individuals
who had had a low or non-high trauma (low trauma fracture =
fracture from a fall from standing height or less) osteoporotic
fracture (excluding skull, nose, digits, hand, foot, ankle, patella)
after the age of 50 years. Vertebral, hip and non-vertebral
fractures were considered both independently and combined.
All participants were of self-reported white European ancestry.
DNA was obtained from peripheral venous blood from all cases
except those recruited from New Zealand, for whom DNA was
obtained from salivary samples using Oragene kits (DNA Genotek,
Ontario, Canada). We have previously demonstrated that DNA
from these two sources have equivalent genotyping characteristics
[20].
After quality control checks including assessment of cryptic
relatedness, ethnicity and genotyping quality, 900 individuals with
low TH BMD and 1055 individuals with high TH BMD were
available for analysis.
The replication cohort consisted of 8928 samples drawn from
nine cohort studies, outlined in Tables S3 and S4 (‘AOGC
replication cohort’) which were directly genotyped, These
replication cases were adult women (age 20–95 years), unselected
with regard to BMD, and who were not screened for secondary
causes of osteoporosis. Replication was also performed in silico in
11,970 adult women from the TwinsUK and Rotterdam, and
deCODE Genetics GWASs [21,22,23], in which association data
were available at LS and FN.
High and low BMD ascertainment was defined according to the
TH score, because this has better measurement precision than FN
BMD [24]. However, neither TwinsUK nor the Rotterdam Study
had TH BMD on the majority of their datasets and therefore were
analysed using the FN measurement for which data were available
on the whole cohort. All replication findings at the hip are
reported therefore for FN BMD. TH and FN BMD are closely
correlated (r = 0.882 in the AOGC dataset), with FN BMD one of
the components of the TH BMD measurement.
Genotyping
Genotyping of the discovery cohort (n = 2036) was performed
using Illumina Infinium II HumHap300 (n = 140), 370CNVDuo
(n= 4), 370CNVQuad (n= 1882) and 610Quad (n= 10) chips at
the University of Queensland Diamantina Institute, Brisbane,
Australia. Genotype clustering was performed using Illumina’s
BeadStudio software; all SNPs with quality scores ,0.15 and all
individuals with ,98% genotyping success were excluded. 289499
SNPs were shared across all chip types. Cluster plots from the 500
most strongly associated loci, were manually inspected and poorly
clustering SNPs excluded from analysis. Following imputation
using the HapMap Phase 2 data, 2,543,887 SNPs were tested for
association with TH and LS BMD (Manhattan plot of association
findings, Figure S1). After data cleaning, minimal evidence of
inflation of test statistics was observed, with a genomic inflation
factor (l) of 1.0282 (qq plot, Figure S2).
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A total of 124 SNPs were successfully genotyped in the AOGC
replication cohort. These replication study SNPs were selected
from the findings of the discovery cohort, either based on the
strength of association (P-value) or following analysis with GRAIL
(n = 45) [25], using as seed data all SNPs previously reported to be
associated with BMD at GWAS significant levels (results for all
replication SNPs presented in Table S5). GRAIL is a bioinfor-
matic program that assesses the strength of relationships between
genes in regions surrounding input SNPs (usually derived from
genetic association studies) and other SNPs or genes associated
with the trait of interest, by assessing their co-occurrence in
PubMed abstracts. Where genes surrounding input SNPs occur
more frequently in abstracts with known associated genes, these
SNPs are more likely themselves also to be associated, and can
thus be prioritized for inclusion in replication studies.
For the replication study, genotyping was performed either by
Applied Biosystems OpenArray (n = 113) or Taqman technology
(n = 11) (Applied Biosystems, Foster City, CA, USA), according to
the manufacturer’s protocol.
Statistical methods
Eleven individuals were removed because of abnormal X-
chromosome homozygosity (X-chromosome homozygosity either
,20.14, or .+0.14). Outliers with regard to autosomal
heterozygosity (either ,0.34225 or .0.357, n= 40) and missing-
ness (.3%, n= 4) were removed. Using an IBS/IBD analysis in
PLINK to detect cryptic relatedness, one individual from 35 pairs
of individuals with pi-hat .0.12 (equivalent to being 3rd degree
relatives or closer) were removed. SNPs with minor allele
frequency ,1% (n= 561), and those not in Hardy-Weinberg
equilibrium (P,1027, n = 170) were then removed, leaving
288,768 SNPs in total. Nine replication SNPs were removed
because of excess missingness (.10%) or because they failed tests
of Hardy-Weinberg equilibrium (P,0.001).
To detect and correct for population stratification EIGEN-
STRAT software was used. We first excluded the 24 regions of
long range LD including the MHC identified in Price et al. before
running the principal components analysis, as suggested by the
authors [26]. Sixteen individuals were removed as ethnic outliers,
leaving 1955 individuals in the final discovery dataset.
Imputation analyses were carried out using Markov Chain
Haplotyping software (MaCH; http://www.sph.umich.edu/csg/
abecasis/MACH/) using phased data from CEU individuals from
release 22 of the HapMap project as the reference set of
haplotypes. We only analyzed SNPs surrounding disease-associat-
ed SNPs that were either genotyped or could be imputed with
relatively high confidence (R2$0.3). For TH measurements, a
case-control association analysis of imputed SNPs was performed
assuming an underlying additive model and including four
EIGENSTRAT eigenvectors as covariates, using the software
package MACH2DAT [27] which accounts for uncertainty in
prediction of the imputed data by weighting genotypes by their
posterior probabilities. For FN and LS BMD analyses, Z-
transformed residual BMD scores (in g/cm2) were generated for
the entire AOGC cohort after adjusting for the covariates age,
age2, and weight, and for centre of BMD measurement. Because
the regression coefficient for BMD on genotype would be biased
by selection for extremes, we adopted the approach detailed in
Kung et al (2009) [28]. Specifically, the regression coefficient of
genotype on BMD was estimated, and subsequently transformed
to the regression coefficient of BMD on genotype through
knowledge of the population variance of the phenotype and the
allele frequencies. For fracture data, analysis was by logistic
regression. Only SNPs achieving GWAS significance were tested
for fracture association. The SNPs used for replication from the
Rotterdam Study were analyzed using MACH2QTL implement-
ed in GRIMP [29]. Data from the discovery and replication
cohorts were combined using the inverse variance approach as
implemented in the program METAL [30].
SNPs associated with BMD were also tested for association with
fracture in the AOGC discovery and replication cohorts (hip,
vertebral, nonvertebral, and all low trauma fractures, age $50
years, as defined above), by logistic regression.
Study power was calculated using the ‘Genetic Power
Calculator’ [31].
Mouse BMD analysis
All animal studies were approved by the MRC Harwell Unit
Ethical Review Committee and are licensed under the Animal
(Scientific Procedures) Act 1986, issued by the UK Government
Home Office Department. Dual-energy X-ray absorptiometry
(DEXA) was performed using a Lunar Piximus densitometer (GE
Medical Systems) and analysed using the Piximus software.
Data availability
Data related to this study will be available to research projects
approved by a Data Access Committee including representatives
of the University of Queensland Research Ethics Committee. For
enquiries regarding access please contact the corresponding
author, MAB (matt.brown@uq.edu.au).
Supporting Information
Figure S1 Manhattan plot of discovery genome-wide association
study findings for BMD at total hip. P = 1025 is indicated by a blue
horizontal line.
Found at: doi:10.1371/journal.pgen.1001372.s001 (0.51 MB TIF)
Figure S2 Genomic control findings. The genomic inflation
factor (l) when reported as the median x2 was 1.0282.
Found at: doi:10.1371/journal.pgen.1001372.s002 (0.36 MB TIF)
Figure S3 SNP association plots for OP-associated regions.
Discovery cohort association significance level is plotted against
the left hand y-axis as -log10(P-values). Genetic coordinates are as
per NCBI build 36.1. Filled circles represent genotyped SNPs, and
outlined diamonds represent imputed SNPs. The recombination
rate (cM/Mb as per HapMap data) is indicated by the purple
dotted line and right hand y-axis. Genes and ESTs are indicated
with their approximate sizes and direction of translation. (A)
Chromosome 16p13 - CLCN7 region. SNP association plot of
findings from TH case-control analysis of AOGC discovery set for
a 100 kb region (1,420 kb to 1,520 kb) of chromosome 16. LD is
indicated by colour scale in relationship to marker rs13336428. (B)
Chromosome 4q22 - IBSP region. SNP association plot of findings
from TH case-control analysis of AOGC discovery set for a
500 kb region (88,700 kb to 89,200 kb) of chromosome 4. LD is
indicated by colour scale in relationship to marker rs1054627. (C)
Chromosome 11p13 - LTBP3 region. SNP association plot of
findings from TH case-control analysis of AOGC discovery set for
a 300 kb region (64,950 kb to 65,250 kb) of chromosome 11. LD
is indicated by colour scale in relationship to marker rs1152620.
(D) Chromosome 6p22 - SOX4 region. SNP association plot of
findings from TH case-control analysis of AOGC discovery set for
a 2 Mb region (20,500 kb to 22,500 kb) of chromosome 6. LD is
indicated by colour scale in relationship to marker rs9466056. (E)
Chromosome 1p22 - TGFBR3 region. SNP association plot of
findings from TH case-control analysis of AOGC discovery set for
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a 1 Mb region (91,800 kb to 92,800 kb) of chromosome 1. LD is
indicated by colour scale in relationship to marker rs7550034.
Found at: doi:10.1371/journal.pgen.1001372.s003 (5.13 MB TIF)
Table S1 Case numbers for the discovery cohort, with BMD
affection status and fracture history.
Found at: doi:10.1371/journal.pgen.1001372.s004 (0.05 MB
DOC)
Table S2 Descriptive statistics for discovery cohort.
Found at: doi:10.1371/journal.pgen.1001372.s005 (0.06 MB
DOC)
Table S3 Replication cohort details.
Found at: doi:10.1371/journal.pgen.1001372.s006 (0.04 MB
DOC)
Table S4 Replication cohort fracture data.
Found at: doi:10.1371/journal.pgen.1001372.s007 (0.04 MB
DOC)
Table S5 Replication study SNPs, beta coefficients and P-values
for analysis of TH, FN and LS. The regression coefficient in the
case-control analysis of TH in the discovery set shows the expected
increase in the log odds ratio of low BMD per addition of allele
A2. The regression coefficients in the TH, FN and LS analyses
refer to the expected increase in standardized BMD per addition
of allele A2 in the discovery set.
Found at: doi:10.1371/journal.pgen.1001372.s008 (0.22 MB
DOC)
Table S6 Association findings in AOGC discovery set for
markers achieving genome-wide significant association with
BMD in previous studies. The regression coefficient in the TH
analysis shows the expected increase in the log odds ratio of low
BMD per addition of allele A2. The regression coefficients in the
FN and LS analyses refer to the expected increase in standardized
BMD per addition of allele A2.
Found at: doi:10.1371/journal.pgen.1001372.s009 (0.12 MB
DOC)
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